Zevra Therapeutics, Inc. (FRA:1GDA)
Germany
· Delayed Price · Currency is EUR 7.35
0.00 (0.00%)
At close: Dec 5, 2025
Zevra Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 84.39 | 23.61 | 27.46 | 10.16 | 28.65 | 13.29 | Upgrade
|
| Revenue Growth (YoY) | 244.60% | -14.02% | 170.26% | -64.53% | 115.61% | 3.50% | Upgrade
|
| Cost of Revenue | 16.33 | 7.42 | 2.17 | 0.22 | 2.06 | 1.31 | Upgrade
|
| Gross Profit | 68.06 | 16.2 | 25.29 | 9.94 | 26.59 | 11.98 | Upgrade
|
| Selling, General & Admin | 73.44 | 54.92 | 35.09 | 15.61 | 9.23 | 8.44 | Upgrade
|
| Research & Development | 18.42 | 42.04 | 39.03 | 19.23 | 9.64 | 8.32 | Upgrade
|
| Amortization of Goodwill & Intangibles | 5.16 | 6.24 | 0.77 | - | - | - | Upgrade
|
| Operating Expenses | 97.02 | 103.2 | 74.89 | 34.84 | 18.86 | 16.76 | Upgrade
|
| Operating Income | -28.96 | -87 | -49.6 | -24.9 | 7.73 | -4.78 | Upgrade
|
| Interest Expense | -8.22 | -7.35 | -1.5 | -0.34 | -0.38 | -7.09 | Upgrade
|
| Interest & Investment Income | 5.16 | 2.18 | 4.54 | 1.51 | 0.26 | 0.09 | Upgrade
|
| Other Non Operating Income (Expenses) | -3.98 | 2.06 | -0.1 | 15.16 | -0.03 | -0.18 | Upgrade
|
| EBT Excluding Unusual Items | -36.01 | -90.12 | -46.66 | -8.57 | 7.59 | -11.97 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | - | - | -0.83 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.04 | -0.02 | 0.61 | -0.58 | -0.01 | - | Upgrade
|
| Other Unusual Items | - | - | - | - | -16.1 | - | Upgrade
|
| Pretax Income | 53.64 | -90.14 | -46.05 | -26.81 | -8.52 | -12.79 | Upgrade
|
| Income Tax Expense | 18.32 | 15.37 | - | -0.03 | 0.03 | -0.03 | Upgrade
|
| Net Income | 35.33 | -105.51 | -46.05 | -26.77 | -8.56 | -12.76 | Upgrade
|
| Preferred Dividends & Other Adjustments | 5.31 | - | - | - | 54.34 | - | Upgrade
|
| Net Income to Common | 30.02 | -105.51 | -46.05 | -26.77 | -62.9 | -12.76 | Upgrade
|
| Shares Outstanding (Basic) | 55 | 46 | 35 | 34 | 30 | 4 | Upgrade
|
| Shares Outstanding (Diluted) | 56 | 46 | 35 | 34 | 30 | 4 | Upgrade
|
| Shares Change (YoY) | 31.47% | 30.46% | 2.79% | 15.87% | 647.72% | 114.79% | Upgrade
|
| EPS (Basic) | 0.55 | -2.28 | -1.30 | -0.78 | -2.11 | -3.21 | Upgrade
|
| EPS (Diluted) | 0.54 | -2.28 | -1.30 | -0.78 | -2.11 | -3.21 | Upgrade
|
| Free Cash Flow | -24.23 | -69.67 | -33.83 | -18.81 | 10.34 | -1.97 | Upgrade
|
| Free Cash Flow Per Share | -0.43 | -1.51 | -0.95 | -0.55 | 0.35 | -0.49 | Upgrade
|
| Gross Margin | 80.65% | 68.59% | 92.09% | 97.81% | 92.81% | 90.18% | Upgrade
|
| Operating Margin | -34.32% | -368.47% | -180.63% | -245.07% | 26.98% | -35.98% | Upgrade
|
| Profit Margin | 35.57% | -446.85% | -167.69% | -263.48% | -219.54% | -96.03% | Upgrade
|
| Free Cash Flow Margin | -28.71% | -295.04% | -123.20% | -185.12% | 36.08% | -14.84% | Upgrade
|
| EBITDA | -23.62 | -80.61 | -48.6 | -23.96 | 7.99 | -4.51 | Upgrade
|
| EBITDA Margin | -27.99% | - | -176.97% | -235.78% | 27.87% | -33.92% | Upgrade
|
| D&A For EBITDA | 5.34 | 6.39 | 1.01 | 0.94 | 0.26 | 0.27 | Upgrade
|
| EBIT | -28.96 | -87 | -49.6 | -24.9 | 7.73 | -4.78 | Upgrade
|
| EBIT Margin | -34.32% | - | -180.63% | -245.07% | 26.98% | -35.98% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.